The European Association of Nuclear Medicine (EANM) is an umbrella organisation comprising 41 national nuclear medicine member societies, 18 non-European affiliated societies and 3,200 individual members from over 80 countries, including physicians, scientists, technologists and other persons working in nuclear medicine or related fields. It is a professional non-profit association representing the nuclear medicine sector to the European institutions and informing the general public and healthcare authorities about ongoing developments within the field.
Health Technology Assessment (HTA) is an essential multidisciplinary process for evidence-based decision-making in healthcare, influencing approval, pricing, and accessibility of medical technologies. The implementation of the European Union HTA Regulation (EU HTAR), in place since January 2025, marks a pivotal shift towards a more harmonized and collaborative approach to HTA across EU Members States at the European level. Nuclear medicine, particularly with the rapid evolution of targeted radionuclide therapy and theranostic approaches, must strategically position itself within this new framework. In this editorial we outline a strategic framework proposal for strengthening HTA integration in the field. By aligning healthcare innovation with regulatory standards for safety, efficacy, and reimbursement, the European Association of Nuclear Medicine (EANM) aims to support equitable patient access, inform national reimbursement decisions, and promote sustainable adoption of nuclear medicine technologies across Europe.
